Fischer Medical Ventures files FY26 BRSR with zero safety incidents

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights
  • Fischer Medical Ventures filed its FY26 BRSR with zero workplace accidents
  • Standalone reporting shows energy use fell to 193.76 GJ from 2,160.89 GJ
  • Employee welfare spending surged to 11.59% of revenue from 0.48%
  • Total headcount reduced to 19 employees under standalone metrics
powered bylight_fuzz_icon
50345006

*this image is generated using AI for illustrative purposes only.

Fischer Medical Ventures submitted its Business Responsibility and Sustainability Report (BRSR) for FY26, highlighting a record of zero workplace accidents and full compliance with safety standards. The filing marks a transition to standalone reporting, offering a focused view of the parent entity’s operational metrics.

The company reported a paid-up capital of ₹65.45 crore as of the fiscal year-end. Operations remain concentrated in India, with one plant and two offices serving markets across nine states. The entity serves a B2B customer base comprising diagnostic centers, hospitals, and government health institutions.

Workforce and Safety Metrics

Fischer Medical Ventures employed 19 individuals at the end of FY26, comprising 16 permanent employees and three non-permanent staff. The workforce is predominantly male, accounting for 78.95% of total headcount. The board of directors includes two women, representing 25% of the total composition.

Safety performance remained strong throughout the year. The Lost Time Injury Frequency Rate (LTIFR) stood at zero for both current and previous fiscal years. No fatalities or high-consequence injuries were recorded. All plants and offices underwent 100% assessment for health and safety practices.

Metric FY26 FY25
Total Employees 19 49
Female Representation 21.05% Data unavailable
LTIFR 0 0
Workplace Accidents 0 0

Environmental Performance

Environmental disclosures reflect a significant reduction in energy consumption compared to the prior year, driven by the shift from consolidated to standalone reporting. Total energy consumed from non-renewable sources fell to 193.76 GJ in FY26, down from 2,160.89 GJ in FY25. Consequently, energy intensity per rupee of turnover dropped sharply to 1.11 GJ/₹ crore from 1,952.30 GJ/₹ crore.

Greenhouse gas emissions followed a similar trajectory. Scope 2 emissions decreased to 38.21 metric tonnes of CO2 equivalent, compared to 436.074 metric tonnes in FY25. Scope 1 emissions were negligible at 0.00 metric tonnes. Water withdrawal totaled 48.94 kiloliters, sourced entirely from third parties.

Governance and Stakeholder Engagement

The company maintained strict governance protocols, reporting no fines, penalties, or regulatory actions during the year. Two complaints were filed by shareholders and two by employees, all of which were resolved with no pending queries. Anti-corruption policies are embedded within the Code of Conduct, and 100% of employees received training on human rights and code of conduct issues.

What the Numbers Show

The divergence between employee turnover rates and benefit coverage warrants attention. While the permanent employee turnover rate rose to 14.29% in FY26 from 9.00% in FY25, the company expanded its welfare spending significantly. Expenditure on employee well-being measures jumped to 11.59% of total revenue, up from just 0.48% in the previous year. This suggests a strategic pivot toward retaining talent through enhanced benefits rather than volume hiring.

Historical Stock Returns for Fischer Medical Ventures

1 Day5 Days1 Month6 Months1 Year5 Years
-0.89%+0.79%-5.73%-1.54%-67.24%0.0%

How might the significant reduction in headcount from 49 to 19 employees impact Fischer Medical Ventures' production capacity and future revenue growth?

Will the shift to standalone reporting continue to mask the company's total environmental footprint, and when will consolidated data be available for accurate year-over-year comparison?

Given the sharp rise in permanent employee turnover to 14.29%, will increased welfare spending effectively retain talent, or does this indicate deeper operational or cultural challenges?

Fischer Medical Ventures
View Company Insights
View All News
like19
dislike

Fischer Medical Ventures hosts investor call on September 7, 2026

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights
  • Fischer Medical Ventures Ltd scheduled an investor and analyst call for September 7, 2026
  • The company disclosed its strategic ecosystem integrating Time Medical, FMV, and FlynnCare brands
  • Key focus areas include AI-enabled medical imaging, population screening, and hospital digitization
  • Nanyang Biologics leverages AI for drug discovery with partnerships including J&J Innovation JLABS
powered bylight_fuzz_icon
50084584

*this image is generated using AI for illustrative purposes only.

Fischer Medical Ventures Limited has scheduled a meeting with analysts and investors on September 7, 2026. The company disclosed the agenda via an exchange filing under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Meeting details

The engagement is designed to update stakeholders on the company's strategic direction. Fischer Medical Ventures described itself as building the world's largest Healthcare AI Solutions Platform, focusing on AI-enabled medical imaging, population-scale screening, and hospital digitization.

Parameter Details
Event Investor/Analyst call
Scheduled date September 7, 2026
Regulatory basis Regulation 30, SEBI LODR 2015

Strategic ecosystem

The presentation highlighted an integrated ecosystem comprising three operating brands:

  • Time Medical: Provides the technology foundation with advanced MRI and diagnostic equipment.
  • FMV: Acts as the commercialization and capital vehicle, integrating diagnostics, AI, and biologics.
  • FlynnCare: Develops AI healthcare applications, including the MIDAS screening ecosystem.

This structure aims to converge technology, commercialization, and AI applications into a single integrated healthcare innovation engine.

Product portfolio

The company outlined its key product verticals:

Medical Imaging

Time Medical offers a full-spectrum MRI portfolio ranging from 0.35T open systems (PICA, AURA) to 7.0T ultra-high field research platforms (Nova 7T). The range includes helium-free magnets and closed-bore systems like the MICA and QUIN series. The company also listed CT imaging solutions (Clarion series) and portable X-ray devices as part of its diagnostic offerings.

AI & Digital Health

FlynnCare's MIDAS platform enables multi-disciplinary early disease detection across eye, oral, mental, and cardiovascular health. The LIVE Dx platform supports population-scale screening with tele-health integration. Additionally, the Clinics 2.0 platform provides EHR, HIS, and practice management solutions.

Biologics & Other Ventures

Nanyang Biologics focuses on AI-driven drug discovery using NVIDIA and HPE infrastructure, with partnerships involving Johnson & Johnson Innovation JLABS. The company also mentioned SpinCare regenerative skin technology and Obelab brain imaging platforms.

Historical Stock Returns for Fischer Medical Ventures

1 Day5 Days1 Month6 Months1 Year5 Years
-0.89%+0.79%-5.73%-1.54%-67.24%0.0%

How will Fischer Medical Ventures plan to monetize its AI-driven drug discovery partnerships with Johnson & Johnson Innovation JLABS in the near term?

What specific regulatory hurdles might the company face in scaling its population-scale screening platform, LIVE Dx, across different international markets?

How does the integration of Time Medical's hardware with FlynnCare's AI software create a competitive moat against pure-play AI healthtech competitors?

Fischer Medical Ventures
View Company Insights
View All News
like17
dislike

More News on Fischer Medical Ventures

1 Year Returns:-67.24%